Tumor Biology

, Volume 34, Issue 4, pp 2141–2146 | Cite as

Clinicopathological significance of BTF3 expression in colorectal cancer

  • Chao-Jie Wang
  • Hanna Frånbergh-Karlson
  • Da-Wei Wang
  • Gunnar Arbman
  • Hong Zhang
  • Xiao-Feng Sun
Research Article


Basic transcription factor 3 (BTF3) is a general RNA polymerase II transcription factor and is also involved in apoptosis regulation. Increasing evidence shows that BTF3 is aberrantly expressed in several kinds of malignancies, but there is no study to analyze BTF3 expression in colorectal cancer (CRC) patients. Applying immunohistochemistry, we detected BTF3 in CRCs (n = 156), the corresponding distant (n = 42), adjacent normal mucosa (n = 96), lymph node metastases (n = 35), and analyzed its relationships with clinicopathological and biological variables. Our results showed that BTF3 staining significantly increased from distant or adjacent normal mucosa to primary CRCs (p < 0.0001) or metastases (p = 0.002 and p < 0.0001). BTF3 was higher in distal cancers than in proximal cancers (57 % vs. 39 %, p = 0.041). It also showed stronger staining in primary CRCs stage I and II than that in stage III and IV (64 % vs. 35 %, p = 0.0004), or metastases (64 % vs. 29 %, p = 0.004). Cancers with better differentiation had a higher expression than those with worse differentiation (56 % vs. 37 %, p = 0.031). There were positive correlations of BTF3 expression with nuclear factor kappa B (NF-κB), RAD50, MRE11, NBS1, and AEG-1 (p < 0.05). In conclusion, BTF3 overexpression may be an early event in CRC development and could be useful biomarker for the early stage of CRCs. BTF3 has positive correlations with NF-κB, RAD50, MRE11, NBS1 and AEG-1, and might influence complex signal pathways in CRC.


Basic transcription factor 3 Biomarker Colorectal cancer Immunohistochemistry 



This study was supported by grants from the Swedish Cancer Foundation, Swedish Research Council and the Health Research Council in the southeast of Sweden.

Conflicts of interest


Supplementary material

13277_2013_745_MOESM1_ESM.tif (5.5 mb)
ESM 1 (TIFF 5593 kb)


  1. 1.
    Zheng XM, Moncollin V, Egly JM, Chambon P. A general transcription factor forms a stable complex with RNA polymerase B (II). Cell. 1987;50(3):361–8.PubMedCrossRefGoogle Scholar
  2. 2.
    Zheng XM, Black D, Chambon P, Egly JM. Sequencing and expression of complementary DNA for the general transcription factor BTF3. Nature. 1990;344(6266):556–9.PubMedCrossRefGoogle Scholar
  3. 3.
    Deng JM, Behringer RR. An insertional mutation in the BTF3 transcription factor gene leads to an early postimplantation lethality in mice. Transgenic Res. 1995;4(4):264–9.PubMedCrossRefGoogle Scholar
  4. 4.
    Li R, Liu XL, Du QF, Zhang S, Luo RC, Zhou SY. Proteome analysis of apoptotic K562 cells induced by harringtonine. Zhonghua Xue Ye Xue Za Zhi. 2004;25(6):323–7.PubMedGoogle Scholar
  5. 5.
    Brockstedt E, Otto A, Rickers A, Bommert K, Wittmann-Liebold B. Preparative high-resolution two-dimensional electrophoresis enables the identification of RNA polymerase B transcription factor 3 as an apoptosis-associated protein in the human BL60-2 Burkitt lymphoma cell line. J Protein Chem. 1999;18(2):225–31.PubMedCrossRefGoogle Scholar
  6. 6.
    Odreman F, Vindigni M, Gonzales ML, Niccolini B, Candiano G, Zanotti B, et al. Proteomic studies on low- and high-grade human brain astrocytomas. J Proteome Res. 2005;4(3):698–708.PubMedCrossRefGoogle Scholar
  7. 7.
    Wang S, Lu LC, Fang WY, Yao KT. Differentially expressed transcription factor-related genes in nasopharyngeal carcinoma and nasopharyngeal tissues. Nan Fang Yi Ke Da Xue Xue Bao. 2007;27(2):146–9.PubMedGoogle Scholar
  8. 8.
    Kusumawidjaja G, Kayed H, Giese N, Bauer A, Erkan M, Giese T, et al. Basic transcription factor 3 (BTF3) regulates transcription of tumor-associated genes in pancreatic cancer cells. Cancer Biol Ther. 2007;6(3):367–76.PubMedCrossRefGoogle Scholar
  9. 9.
    Roy L, Laboissière S, Abdou E, Thibault G, Hamel N, Taheri M, et al. Proteomic analysis of the transitional endoplasmic reticulum in hepatocellular carcinoma: an organelle perspective on cancer. Biochim Biophys Acta. 2010;1804(9):1869–81.PubMedCrossRefGoogle Scholar
  10. 10.
    Dunican DS, McWilliam P, Tighe O, Parle-McDermott A, Croke DT. Gene expression differences between the microsatellite instability (MIN) and chromosomal instability (CIN) phenotypes in colorectal cancer revealed by high-density cDNA array hybridization. Oncogene. 2002;21(20):3253–7.PubMedCrossRefGoogle Scholar
  11. 11.
    Delattre O, Olschwang S, Law DJ, Melot T, Remvikos Y, Salmon RJ, et al. Multiple genetic alterations in distal and proximal colorectal cancer. Lancet. 1989;2(8659):353–6.PubMedCrossRefGoogle Scholar
  12. 12.
    Gervaz P, Bouzourene H, Cerottini JP, Chaubert P, Benhattar J, Secic M, et al. Dukes B colorectal cancer: distinct genetic categories and clinical outcome based on proximal or distal tumor location. Dis Colon Rectum. 2001;44(3):364–72.PubMedCrossRefGoogle Scholar
  13. 13.
    Miyakura Y, Sugano K, Konishi F, Ichikawa A, Maekawa M, Shitoh K, et al. Extensive methylation of hMLH1 promoter region predominates in proximal colon cancer with microsatellite instability. Gastroenterology. 2001;121(6):1300–9.PubMedCrossRefGoogle Scholar
  14. 14.
    Thibodeau SN, Bren G, Schaid D. Microsatellite instability in cancer of the proximal colon. Science. 1993;260(5109):816–9.PubMedCrossRefGoogle Scholar
  15. 15.
    Li FY, Lai MD. Colorectal cancer, one entity or three. J Zhejiang Univ Sci B. 2009;10(3):219–29.PubMedCrossRefGoogle Scholar
  16. 16.
    Rospert S, Dubaquié Y, Gautschi M. Nascent-polypeptide-associated complex. Cell Mol Life Sci. 2002;59(10):1632–9.PubMedCrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2013

Authors and Affiliations

  • Chao-Jie Wang
    • 1
    • 2
  • Hanna Frånbergh-Karlson
    • 2
  • Da-Wei Wang
    • 3
  • Gunnar Arbman
    • 4
  • Hong Zhang
    • 5
  • Xiao-Feng Sun
    • 6
  1. 1.Department of OncologyHenan Provincial People’s Hospital and People’s Hospital of Zhengzhou UniversityZhengzhouChina
  2. 2.Faculty of Health Sciences, Division of Oncology, Department of Clinical and Experimental MedicineUniversity of LinköpingLinköpingSweden
  3. 3.Department of StomatologyThe Third Hospital of Hebei Medical UniversityShijiazhuangChina
  4. 4.Department of Surgery, Vrinnevi HospitalUniversity of LinköpingNorrköpingSweden
  5. 5.School of MedicineÖrebro UniversityÖrebroSweden
  6. 6.Faculty of Health Sciences, Division of Oncology, Department of Clinical and Experimental Medicine, County Council of ÖstergötlandUniversity of LinköpingLinköpingSweden

Personalised recommendations